Comparison · NCT02145468-sae
Losmapimod 7.5 mg BID vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Losmapimod 7.5 mg BID vs Placebo: serious adverse events. Trial comparisons, record NCT02145468-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02145468-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.211 | 0.192 | 0.23 | wilson | |
| Risk in group 2 | 0.184 | 0.167 | 0.203 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0262 | -0.000273 | 0.0527 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.998 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.998 | 1.39 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Losmapimod 7.5 mg BID than on Placebo | 38.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Losmapimod 7.5 mg BID | Participants received losmapimod 7.5 mg tablets via oral route, BID, according to the randomization schedule for 12 weeks in addition to standard of care, and were followed for an additional 12 weeks after completing treatment, for a total study duration of 24 weeks. | 363 | 1,724 | EG001 |
| Group 2 | Placebo | Participants received losmapimod matching placebo tablets via oral route, BID, according to the randomization schedule for 12 weeks in addition to standard of care, and were followed for an additional 12 weeks after completing treatment, for a total study duration of 24 weeks. | 323 | 1,752 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to Week 24)
Source ClinicalTrials.gov
Trial
- Title
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
- NCT number
- NCT02145468
- Phases
- PHASE3
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2017-06-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02145468?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02145468-sae